Boone NW - Search Results

1

Less is more: a cost benefit analysis of a changed posology for nivolumab.

Boone NW, van Bodegraven AA. Boone NW, et al. Eur J Clin Pharmacol. 2020 May;76(5):739-740. doi: 10.1007/s00228-020-02839-7. Epub 2020 Jan 28. Eur J Clin Pharmacol. 2020. PMID: 31993685 No abstract available.

2

The nocebo effect challenges the non-medical infliximab switch in practice.

Boone NW, Liu L, Romberg-Camps MJ, Duijsens L, Houwen C, van der Kuy PHM, Janknegt R, Peeters R, Landewé RBM, Winkens B, van Bodegraven AA. Boone NW, et al. Eur J Clin Pharmacol. 2018 May;74(5):655-661. doi: 10.1007/s00228-018-2418-4. Epub 2018 Jan 24. Eur J Clin Pharmacol. 2018. PMID: 29368188 Free PMC article.

3

Editorial: nocebo effect and switching to biosimilars.

van Bodegraven AA, Boone NW. van Bodegraven AA, et al. Among authors: boone nw. Aliment Pharmacol Ther. 2018 Mar;47(6):850-851. doi: 10.1111/apt.14509. Aliment Pharmacol Ther. 2018. PMID: 29446141 No abstract available.

4

Non-specific treatment effects and the patient perception of costly drug therapy.

Boone NW. Boone NW. Eur J Clin Pharmacol. 2018 Oct;74(10):1363. doi: 10.1007/s00228-018-2491-8. Epub 2018 May 31. Eur J Clin Pharmacol. 2018. PMID: 29855656 No abstract available.

5

Single dose tocilizumab for COVID-19 associated cytokine storm syndrome: Less is more.

Boone NW, Moes DJAR, Ramiro S, Mostard RLM, Magro-Checa C, van Dongen CMP, Gronenschild M, van Haren E, Buijs J, de Vries A, Peeters R, Landewé RBM, Wong DR. Boone NW, et al. Br J Clin Pharmacol. 2023 Feb 15. doi: 10.1111/bcp.15690. Online ahead of print. Br J Clin Pharmacol. 2023. PMID: 36791777 Free article.

6

Cotreatment with methotrexate in routine care patients with rheumatoid arthritis receiving biological treatment yields better outcomes over time.

Boone NW, Sepriano A, van der Kuy PH, Janknegt R, Peeters R, Landewé RBM. Boone NW, et al. RMD Open. 2019 Jan 22;5(1):e000836. doi: 10.1136/rmdopen-2018-000836. eCollection 2019. RMD Open. 2019. PMID: 30740244 Free PMC article.

7

Evaluating patient reported outcomes in routine practice of patients with rheumatoid arthritis treated with biological disease modifying anti rheumatic drugs (b-DMARDs).

Boone NW, Teeuwisse P, van der Kuy PH, Janknegt R, Landewé RB. Boone NW, et al. Springerplus. 2015 Aug 28;4:462. doi: 10.1186/s40064-015-1247-5. eCollection 2015. Springerplus. 2015. PMID: 26339563 Free PMC article.

8

How to select a best-value biological medicine? A practical model to support hospital pharmacists.

Barbier L, Vandenplas Y, Boone N, Huys I, Janknegt R, Vulto AG. Barbier L, et al. Am J Health Syst Pharm. 2022 Nov 7;79(22):2001-2011. doi: 10.1093/ajhp/zxac235. Am J Health Syst Pharm. 2022. PMID: 36002245 Free PMC article.

9

Routine Assessment of Patient Index Data 3 (RAPID3) alone is insufficient to monitor disease activity in rheumatoid arthritis in clinical practice.

Boone NW, Sepriano A, van der Kuy PH, Janknegt R, Peeters R, Landewé RBM. Boone NW, et al. RMD Open. 2019 Nov 28;5(2):e001050. doi: 10.1136/rmdopen-2019-001050. eCollection 2019. RMD Open. 2019. PMID: 31908842 Free PMC article.

10

Tissue plasminogen activator (tPA) in the management of predominantly hemorrhagic age-related macular degeneration, milligram/milliliter or microgram/milliliter?

Boone NW, van Leeuwen RW. Boone NW, et al. Clin Ophthalmol. 2012;6:145. doi: 10.2147/OPTH.S28071. Epub 2012 Jan 19. Clin Ophthalmol. 2012. PMID: 22291455 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

13 results

Search Page

Filters